Overview

Public BiotechLSD

Leading neuroscience biopharma with marketed products INGREZZA and CRENESSITY. Phase 3 programs include osavampator for depression and direclidine for schizophrenia. Strong pipeline of muscarinic agonists.

Visit Website

San Diego, CA

$13.9B
Market Cap
1992
Founded
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline(1)

Unknown·N/A·LSD

Investigating Lysosomal Storage Diseases in Minority Groups

Lysosomal Storage Disorders
NCT02120235